Wall Street analysts predict that KITOV PHARMA LT/S (NASDAQ:KTOV) will post earnings per share of ($0.01) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for KITOV PHARMA LT/S’s earnings. The company is expected to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that KITOV PHARMA LT/S will report full-year earnings of ($0.03) per share for the current year. For the next fiscal year, analysts expect that the firm will post earnings of ($0.02) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for KITOV PHARMA LT/S.
Several equities analysts recently weighed in on KTOV shares. HC Wainwright reaffirmed a “buy” rating and set a $12.50 price objective on shares of KITOV PHARMA LT/S in a research report on Tuesday, June 19th. ValuEngine raised shares of KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research raised shares of KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a research report on Friday, June 15th.
KITOV PHARMA LT/S Company Profile
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with MarketBeat.com's FREE daily email newsletter.